Bo
Boehringer Ingelheim
Ingelheim DEFounded 188553,000 employees
Private CappharmaPrivateRespiratoryOncologyMetabolicImmunology
Platform: Bispec & SM
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Talainavolisib | BOE-7693 | Phase 2/3 | 2 | PD-L1 | FTD | ||
| Rimatuximab | BOE-334 | Phase 2/3 | 1 | PLK4 | MGFSGS | ||
| Adagravorutinib | BOE-5895 | Phase 3 | 3 | IL-23 | IgANET | ||
| Nidacagene | BOE-4645 | Phase 2 | 2 | CDK4/6 | Urothelial Ca |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)